Norepinephrine dosing in France: Time to move forward!

IF 3.7 3区医学 Q1 ANESTHESIOLOGY

Anaesthesia Critical Care & Pain Medicine Pub Date : 2024-05-29 DOI:10.1016/j.accpm.2024.101397

Isabelle Goyer , Ines Lakbar , Yonathan Freund , Bruno Lévy , Marc Leone

{"title":"Norepinephrine dosing in France: Time to move forward!","authors":"Isabelle Goyer , Ines Lakbar , Yonathan Freund , Bruno Lévy , Marc Leone","doi":"10.1016/j.accpm.2024.101397","DOIUrl":null,"url":null,"abstract":"<div><p>Norepinephrine is the first-line vasopressor used in acute cardio-circulatory failure. At the bedside, its dose is critical as it serves to determine the severity of patients, to compare the patients between different studies, and to start specific interventions. Recently, several investigators underlined differences in the expression of norepinephrine doses according to countries and manufacturers. For various reasons, all norepinephrine products are processed to a salt formulation thereby generating a stable and soluble conjugated acid in a slightly acidic solution. Depending on the salt used, the total weight will differ, but the weight of pure norepinephrine base is the same. This results in at-risk situations with large variations in terms of practices, evaluation and treatment. In this technical note, we summarized the evidence and provided a few suggestions to improve the practices at different levels.</p></div>","PeriodicalId":48762,"journal":{"name":"Anaesthesia Critical Care & Pain Medicine","volume":"43 4","pages":"Article 101397"},"PeriodicalIF":3.7000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352556824000559/pdfft?md5=d6518e3ebde671b717ea1b41f960e3a5&pid=1-s2.0-S2352556824000559-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia Critical Care & Pain Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352556824000559","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Norepinephrine is the first-line vasopressor used in acute cardio-circulatory failure. At the bedside, its dose is critical as it serves to determine the severity of patients, to compare the patients between different studies, and to start specific interventions. Recently, several investigators underlined differences in the expression of norepinephrine doses according to countries and manufacturers. For various reasons, all norepinephrine products are processed to a salt formulation thereby generating a stable and soluble conjugated acid in a slightly acidic solution. Depending on the salt used, the total weight will differ, but the weight of pure norepinephrine base is the same. This results in at-risk situations with large variations in terms of practices, evaluation and treatment. In this technical note, we summarized the evidence and provided a few suggestions to improve the practices at different levels.

查看原文本刊更多论文

法国的去甲肾上腺素剂量：是时候向前迈进了！

去甲肾上腺素是用于急性心循环衰竭的一线血管抑制剂。在床边，去甲肾上腺素的剂量至关重要，因为它可用于确定患者的严重程度、比较不同研究中的患者以及启动特定的干预措施。最近，一些研究人员强调了不同国家和制造商在去甲肾上腺素剂量表达上的差异。由于种种原因，所有去甲肾上腺素产品都要加工成盐配方，从而在微酸性溶液中生成稳定、可溶的共轭酸。根据所用盐的不同，总重量也会不同，但纯去甲肾上腺素碱的重量是相同的。这就造成了在实践、评估和治疗方面存在巨大差异的高危情况。在本技术说明中，我们总结了相关证据，并为改进不同层面的实践提出了一些建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anaesthesia Critical Care & Pain Medicine ANESTHESIOLOGY-

CiteScore

6.70

自引率

5.50%

发文量

150

审稿时长

18 days

期刊介绍： Anaesthesia, Critical Care & Pain Medicine (formerly Annales Françaises d''Anesthésie et de Réanimation) publishes in English the highest quality original material, both scientific and clinical, on all aspects of anaesthesia, critical care & pain medicine.